Healthcare Industry News:  benign prostatic hyperplasia 

Devices Urology

 News Release - April 23, 2009

Urologix Announces Launch of New Catheter and Scientific Presentations at 2009 American Urological Association Annual Meeting

Launch of CTC Advance Short Catheter Designed for Smaller Glands

Clinical Effectiveness with Customized High Energy Settings Demonstrated in Scientific Presentation

5 Year Durability of Urologix’ Treatment Reinforced in Second Presentation

MINNEAPOLIS--(HSMN NewsFeed)--Urologix(R), Inc. (NASDAQ:ULGX ) is pleased to announce the launch of the CTC Advance ™ Short treatment catheter at the 2009 American Urological Association Annual Meeting in Chicago, Illinois being held April 25-29, 2009. In addition to this new BPH treatment catheter, we are proud to have the AUA acceptance of two moderated poster presentations highlighting the data from clinical studies of the Urologix Cooled ThermoTherapy treatment. Urologix is the pioneer of Cooled ThermoTherapy for the treatment of enlarged prostate disease in the comfortable setting of a physician's office and we are proud to highlight the newest member of our product family and the extensive peer-reviewed clinical evidence supporting the effectiveness of our technology. Urologix’ Cooled ThermoTherapy™ is a customizable and durable nonsurgical treatment for enlarged prostate disease, also known as benign prostatic hyperplasia (BPH).

The new Urologix CTC Advance Short tailors the size and power setting of the CTC Advance catheter to treat smaller prostate glands while maintaining the improvements in cooling and flexibility compared to the predecessor CTC catheter. The CTC Advance Short is another example of Urologix’ commitment to provide the Urologist a broad array of effective microwave catheters to treat the largest indicated patient population of any transuretheral microwave device. Market feedback from the first cases with the CTC Advance Short supports the goal of improved ease of use and treatment toleration.

"My experience with the Urologix CTC Advance and the new CTC Advance Short catheter design is that the new catheters allow for easier insertion and placement compared to the older generation catheter and other competitive devices that I have used. The power of the Urologix cooling system also provides for improved patient comfort during the treatment," said Dr. S. Tsi, The Urology Center of Southern California.

We are proud to announce the upcoming presentation of two new scientific posters on Wednesday April 29th at the AUA. The first presentation on Wednesday by Dr. William J. Utz, Urology Associates, Minneapolis, MN is titled “Effects of Urethral Temperature on Patient Outcomes for benign prostatic hyperplasia with Cooled High Energy TUMT”. The second presentation by Dr. Claus G. Roehrborn, Professor and Chairman of Urology at University of Texas Southwestern Medical Center, is titled “5-Year Results of a Multi-Center Study of Cooled ThermoTherapy for benign prostatic hyperplasia”.

"Completing the CTC Advance catheter family is an important milestone for Urologix. This means that with our wide range of CTC Advance catheter sizes and power settings urologists can tailor the treatment to fit the complete spectrum of their patients’ needs: from a safe and effective alternative treatment to BPH medication to a safe and effective treatment for those patients who are experiencing obstructive symptoms or acute retention and wish to avoid surgery. I am particularly pleased to see the presentation of the new clinical evidence and to introduce the CTC Advance Short at the American Urological Association’s Annual Meeting this year,” stated Stryker Warren, Jr. CEO.

The CTC Advance catheter works with both the Urologix CoolWave® and Targis® control units. As compared to the prior generation CTC microwave catheter, CTC Advance is 72% more flexible in the treatment area and provides 50% more cooled surface area proximal to the treatment area. The CTC Advance Short microwave catheter has been used to treat patients in the US during a pre-launch period since April 3, 2009. Early physician feedback confirms that the improvements in patient toleration and good outcomes we have heard from the market since the launch of the CTC Advance are expected to translate to this new catheter.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix’ products include the CoolWave®, Targis® and Prostatron® control units and the CTC Advance™, Cooled ThermoCath® , Targis® and Prostaprobe® catheter families. All of Urologix’ products utilize Cooled ThermoTherapy™ - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH. Additional product information including the Instructions for Use can be accessed at

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, statements about the Company’s plans and future revenue and operating performance, statements about the Company’s ability to develop and market new products, and statements about the Company-owned Cooled ThermoTherapy mobile service. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2008 and other documents filed with the Securities and Exchange Commission.

Source: Urologix

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.